Yüklüyor......
Endurance of erythrocyte series in chemotherapy
Hematopoietic bone marrow toxicity is most often the limiting factor for chemotherapy doses. Increasing the intensity of chemotherapy doses (higher doses or more frequent administration) would improve antitumor effects, but the hematological toxicity does not allow these dose increases. This study e...
Kaydedildi:
| Yayımlandı: | Exp Ther Med |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7604759/ https://ncbi.nlm.nih.gov/pubmed/33149778 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2020.9344 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|